Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Working Capital Turnover Ratio for the year ending December 31, 2023: 0.00

Anebulo Pharmaceuticals Inc Working Capital Turnover Ratio is 0.00 for the year ending December 31, 2023, a 0.00% change year over year. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate revenue. It is calculated by dividing the revenue by the working capital. This ratio indicates the number of times the company's working capital is converted into revenue during a specific period. A higher working capital turnover ratio suggests more efficient utilization of working capital in revenue generation.
  • Anebulo Pharmaceuticals Inc Working Capital Turnover Ratio for the year ending December 31, 2022 was 0.00, a 0.00% change year over year.
  • Anebulo Pharmaceuticals Inc Working Capital Turnover Ratio for the year ending December 31, 2021 was 0.00, a 0.00% change year over year.
  • Anebulo Pharmaceuticals Inc Working Capital Turnover Ratio for the year ending December 31, 2020 was 0.00.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email